ATI 50001

Drug Profile

ATI 50001

Alternative Names: A-201; ATI-50001

Latest Information Update: 12 May 2017

Price : $50

At a glance

  • Originator Rigel Pharmaceuticals
  • Developer Aclaris Therapeutics
  • Class
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alopecia

Most Recent Events

  • 15 Mar 2017 Aclaris Therapeutics completes a phase I trial in Alopecia in USA
  • 15 Mar 2017 Aclaris Therapeutics plans a phase II trial for Alopecia in USA (PO)
  • 07 Dec 2016 Phase-I clinical trials in Alopecia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top